Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
12/11/24 Candel (CADL) CAN-2409 for Prostate Cancer Subscribers Only Subscribers Only Subscribers Only
12/10/24 NewAmsterdam (NAMS) Obicetrapib for Dyslipidemia / Hypercholesterolemia Subscribers Only Subscribers Only Subscribers Only
12/10/24 Incyte (INCY) Monjuvi for Follicular Lymphoma (FL) Subscribers Only Subscribers Only Subscribers Only
12/10/24 CervoMed (CRVO) Neflamapimod for Lewy Body Dementia (LBD) Subscribers Only Subscribers Only Subscribers Only
12/10/24 Sutro Biopharma (STRO) Luvelta for Ovarian Cancer Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
02/29/2024 Subscribers Only Subscribers Only Trial Announcement - Initiation
06/30/2024 Subscribers Only Subscribers Only Trial Announcement - Trial Completion (Emerging Markets)
01/01/2025 - 06/30/2024 Subscribers Only Subscribers Only Trial Data - Final Results
09/12/2024 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/30/2024 Subscribers Only Subscribers Only Trial Data - Updated Results